靶向成纤维细胞生长因子受体药物在晚期胆管癌中的研究进展  

Advances in medicine targeting fibroblast growth factor receptors in the treatment of advanced cholangiocarcinoma

作　　者：王艳春 钟志鸿 陈曦 张妍 Wang Yanchun;Zhong Zhihong;Chen Xi;Zhang Yan(Department of Oncology,the 900th Hospital of Joint Logistic Support Force,PLA,Fujian Medical University,Fuzhou 350025,China;Department of Gastroenterology,People’s Hospital of Fuan City,Ningde 355000,China)

机构地区：[1]解放军联勤保障部队第九○○医院肿瘤内科,福州350025 [2]福安市人民医院消化内科,宁德355000

出　　处：《中华肝胆外科杂志》2022年第12期951-955,共5页Chinese Journal of Hepatobiliary Surgery

基　　金：福建省自然科学基金(2018J01352)。

摘　　要：胆管癌是一种异质性高、预后差的胆道恶性肿瘤, 手术是早期胆管癌的唯一治愈手段, 但约2/3的患者初诊时已为晚期。晚期胆管癌患者的一线化疗方案并未带来可期的生存期。近年来, 随着二代基因测序技术的发展, 胆管癌中的潜在靶点被不断发现, 一系列临床试验也随之展开。其中, 靶向成纤维细胞生长因子受体(FGFRs)药物的临床试验得到了可喜的结果。本文就靶向FGFRs药物在晚期胆管癌中的治疗现状及研究进展进行综述。Cholangiocarcinoma is a malignant tumor of the biliary tract with high heterogeneity and poor prognosis.Surgery is the only cure for early cholangiocarcinoma,but about two thirds of the patients are already advanced at the time of initial diagnosis.First-line chemotherapy in patients with advanced cholangiocarcinoma does not lead to viable survival.In recent years,with the development of second-generation sequencing technology,potential targets in cholangiocarcinoma have been continuously discovered,and a series of clinical trials have been carried out accordingly.Among them,clinical trials of drugs targeting fibroblast growth factor receptors(FGFRs)have yielded promising results.This article reviews the current status and research progress of drugs targeting FGFRs in the treatment of advanced cholangiocarcinoma.

关 键 词：胆管肿瘤 受体 成纤维细胞生长因子 分子靶向治疗 

分 类 号：R735.8[医药卫生—肿瘤]